Comparison of One-Year Outcomes Between the ihtDEStiny BD Stent and the Durable-Polymer Everolimus- and Zotarolimus-Eluting Stents: A Propensity-Score-Matched Analysis
| Autor: | Juan Sanchis, Mario Sadaba Sagredo, Jose A. Hurtado Martinez, Pedro K. Rivera Aguilar, Imanol Otaegui, José M. de la Torre Hernández, Xavier Oliva, Alfonso Torres, Bruno García del Blanco, Juan M. Casanova Sandoval, M. Alvarez, Eduard Fernandez Nofrerias, Vicente Peral Disdier, Xavier Carrillo Suarez, Felipe Hernández, Fermin Sainz Laso, Fernando Lozano Ruiz-Poveda, Eduardo Pinar Bermúdez, Belen Cid, José Moreu, Raymundo Ocaranza Sánchez, Ramiro Trillo, Miren Telleria, Xavier Freixa |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Polymers medicine.medical_treatment 030204 cardiovascular system & hematology Prosthesis Design Coronary artery disease 03 medical and health sciences 0302 clinical medicine Percutaneous Coronary Intervention Absorbable Implants medicine Clinical endpoint Humans Zotarolimus 030212 general & internal medicine Myocardial infarction Everolimus Propensity Score Sirolimus business.industry Stent Drug-Eluting Stents General Medicine medicine.disease Surgery Treatment Outcome Drug-eluting stent Propensity score matching Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Cardiovascular revascularization medicine : including molecular interventions. 31 |
| ISSN: | 1878-0938 |
| Popis: | Objectives We sought to evaluate clinical outcomes in patients treated with the drug-eluting stent ihtDEStiny BD. Background The ihtDEStiny BD stent is a metallic sirolimus eluting stent with a biodegradable polymer with both drug and polymer coating the abluminal surface of the stent and balloon. Methods In this study, the clinical outcomes of a multicenter prospective registry of patients treated with this stent (DEStiny group) were analyzed and compared with those of a control group of patients treated with durable polymer everolimus or zotarolimus eluting stents (CONTROL group) paired by propensity score matching . Primary outcome was the target vessel failure (TVF) at 12 months defined as a composite of cardiac death, target vessel myocardial infarction (TV-MI) and target vessel revascularization (TVR). Results A total of 350 patients were included in the DESTtiny group. The control group consisted initially of 1368 patients, but after matching (1:1) 350 patients were selected as CONTROL group. The baseline clinical, angiographic and procedural characteristics were quite comparable in both groups. At 12 months follow up the TVF was 6.6% in DEStiny group and 6.3% in CONTROL group (p = 0.8). No differences were observed for any of the individual components of the primary endpoint: cardiac death 1.1% vs. 1.4%, TV-MI 3.4% vs. 3.7% and TVR 2.6% vs. 2.3% respectively. Conclusions The use of ihtDEStiny stent in real practice is associated with a clinical performance at 12 months follow up that appears to be non-inferior to the most widely used and largely evidence supported durable polymer drug eluting stents. A longer follow up is warranted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect